June 2016 Stockton Israel (STK), a leader in innovative botanical based crop protection signed an extension to its joint research agreement with Yeda Research and Development Company Ltd., for the joint research with Prof. Assaf Aharoni's Plant ... BioSpace, 2 weeks ago
Stockton Israel Extends Research Agreement with Yeda - Farm Chemicals International, 2 weeks ago
Stockton Group, Yeda Company sign extension to joint research agreement - Fresh Plaza, 2 weeks ago
TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, announces the grant by the European Patent Office of the ...PharmaBiz, 1 day ago TxCell Exercises Option from Weizmann Institute of Science Following Effective Grant of Broad CAR-Treg Patent in Europe Wallstreet Online, 3 days ago BRIEF-TxCell exercises option from Weizmann institute Reuters UK, 3 days ago
BiondVax Pharma (NASDAQ:BVXV) Zacks Investment Research raised their FY2016 earnings per share (EPS) estimates for shares of BiondVax Pharma in a research report issued to clients and investors on Monday, Zacks Investment Research reports. Zacks ...American Banking News - Earnings, 1 month ago BiondVax Pharma (BVXV) Forecasted to Earn Q1 2016 Earnings of ($0.01) Per Share Ticker Report, 1 month ago
XTL BIOPHARMACEUTICALS : Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
/ Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because ...4 Traders, 3 weeks ago Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market Equities.com, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!